Tom Powles: Adjuvant pembrolizumab in clear cell renal cancer for the 1st time (KN564)
Tom Powles, Director of Barts Cancer Center, recently shared on X:
“Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high-risk clear cell renal cancer for the 1st time (KN564). This further tips the balance towards giving adjuvant pembrolizumab in this setting.”
Read further.
Source: Tom Powles/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023